Zhejiang Cancer Hospital
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Drug: Nimotuzumab
- Radiation: Radiation
|Ages eligible for Study||65 Years and older|
|Genders eligible for Study||All|
|Accepts Healthy Volunteers||No|
- Previously untreated and histologically confirmed locoregionally advanced nasopharyngeal carcinoma
- A history of another invasive cancer, prior RT to the head and neck area, prior cytotoxic chemotherapy or anti-EGFR therapy or the presence of any serious medical conditions, supposed to live less than 6 months.
Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
- Xiaozhong ChenrecruitingHangzhou, Zhejiang, China, 310022
31 December, 2016
18 January, 2017